Trilaciclib

• CAT Number: I011412
• CAS Number: 1374743-00-6
• Molecular Formula: C24H30N8O
• Molecular Weight: 446.559
• Purity: ≥95%
• Target: CDK4/6
• Storage: Store at -20°C
• IUPAC Name: 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyrazino[5,6]pyrrolo[1,2-d]pyrimidine-9,1/'-cyclohexane]-6-one
• InChI: InChI=1S/C24H30N8O/c1-30-9-11-31(12-10-30)18-5-6-20(25-15-18)28-23-26-14-17-13-19-22(33)27-16-24(7-3-2-4-8-24)32(19)21(17)29-23/h5-6,13-15H,2-4,7-12,16H2,1H3,(H,27,33)(H,25,26,28,29)
• InChIKey: PDGKHKMBHVFCMG-UHFFFAOYSA-N
• SMILES: CN1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6

Trilaciclib (CAT: I011412) is a small-molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). It exerts its pharmacologic action by specifically binding to and inhibiting CDK4/6, enzymes involved in cell cycle progression. Trilaciclib has been developed as a myelopreservation agent with the potential to protect hematopoietic stem and progenitor cells from the damaging effects of chemotherapy. By temporarily inducing cell cycle arrest in these cells, trilaciclib aims to reduce chemotherapy-induced myelosuppression, including neutropenia and thrombocytopenia. Trilaciclib is being investigated as a supportive care therapy to enhance the tolerability and reduce the side effects of chemotherapy in patients with various types of cancer.

Reference

1: Bisi JE, Sorrentino JA, Roberts PJ, Tavares FX, Strum JC. Preclinical
Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of
Chemotherapy-Induced Myelosuppression. Mol Cancer Ther. 2016 May;15(5):783-93.
doi: 10.1158/1535-7163.MCT-15-0775. Epub 2016 Jan 29. PubMed PMID: 26826116.